Concepedia

Publication | Closed Access

Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.

623

Citations

12

References

2003

Year

Wm. Kevin Kelly, Victoria M. Richon, Owen A. O’Connor, Tracy Curley, Barbara MacGregor-Curtelli, William P. Tong, Mark Klang, Lawrence B. Schwartz, Stacie Richardson, Eddie Rosa,
PubMed

Abstract

Daily i.v. SAHA is well tolerated, inhibits the biological target in vivo, and has antitumor activity in solid and hematological tumors.

References

YearCitations

Page 1